Table 3 DAS28-CRP value and HAQ-DI scores between treatment groups at weeks 12 and 24
ITT analysis | PP analysis | |||
|---|---|---|---|---|
Test (n = 112) | Reference (n = 56) | Test (n = 107) | Reference (n = 52) | |
DAS28 CRP value | ||||
Change from baseline at week 12* | −2.1 (1.06) | − 2.0 (1.36) | −2.2 (1.02) | − 2.1 (1.24) |
MD (±SE) | −0.08 (0.19) | −0.04 (0.19) | ||
95% CI | (−0.5, 0.3) | (− 0.4, 0.3) | ||
p value | 0.968 | 0.945 | ||
Change from baseline at week 24* | −3.3 (1.58) | −3.2 (1.53) | −3.5 (1.48) | −3.4 (1.32) |
MD (±SE) | −0.12 (0.26) | −0.09 (0.24) | ||
95% CI | (−0.6, 0.4) | (−0.6, 0.4) | ||
p value | 0.920 | 0.997 | ||
HAQ-DI | ||||
Change from baseline at week 12* | −1.0 (0.51) | −0.9 (0.50) | −1.0 (0.51) | − 1.0 (0.44) |
MD (±SE) | −0.02 (0.08) | −0.00 (0.08) | ||
95% CI | (−0.2, 0.1) | (−0.2, 0.2) | ||
p value | 0.679 | 0.588 | ||
Change from baseline at week 24* | −1.3 (0.54) | −1.3 (0.58) | − 1.4 (0.52) | −1.3 (0.50) |
MD (±SE) | −0.06 (0.09) | −0.03 (0.09) | ||
95% CI | (−0.2, 0.1) | (−0.2, 0.1) | ||
p value | 0.653 | 0.449 | ||